Disc Medicine
Disc Medicine develops new therapies for rare blood disorders, focusing on hematologic diseases and conducting clinical trials to evaluate drug efficacy.
Company Overview
Disc Medicine focuses on developing new therapies for rare blood disorders. The company is dedicated to addressing both rare genetic disorders and widespread chronic hematologic diseases. It is committed to turning scientific discoveries into useful therapies that have the potential to save lives, alleviate suffering, and improve the quality of life for patients.
Location
Disc Medicine is located at 321 Arsenal Street, Suite 101, Watertown, MA 02472. This strategic location supports its efforts in conducting cutting-edge research and clinical trials aimed at developing effective treatments for hematologic diseases.
Therapeutic Pipeline
Disc Medicine's therapeutic pipeline includes several promising candidates targeting various blood disorders. Key developments include Bitopertin, being investigated as a potential treatment for erythropoietic porphyrias; DISC-0974, an injectable monoclonal antibody targeting hemojuvelin for anemia of inflammation; and DISC-3405, another injectable monoclonal antibody targeting TMPRSS6 for diseases related to iron overload.
Clinical Trials
Disc Medicine conducts clinical trials to evaluate the efficacy and safety of its drug candidates. These trials are essential to ensure that their therapies meet regulatory standards and provide significant benefits to patients with hematologic diseases.